A phase 3, randomized, open-label study evaluating DN-101 in combination with docetaxel in androgen-independent prostate cancer (AIPC) (ASCENT-2).

Trial Profile

A phase 3, randomized, open-label study evaluating DN-101 in combination with docetaxel in androgen-independent prostate cancer (AIPC) (ASCENT-2).

Discontinued
Phase of Trial: Phase III

Latest Information Update: 26 Feb 2017

At a glance

  • Drugs Calcitriol (Primary) ; Docetaxel (Primary) ; Dexamethasone; Prednisone
  • Indications Prostate cancer
  • Focus Registrational; Therapeutic Use
  • Acronyms ASCENT-2
  • Sponsors Transcept Pharmaceuticals Inc
  • Most Recent Events

    • 09 May 2012 Additional trial locations added as reported by German Clinical Trials Register record.
    • 09 May 2012 New source identified and integrated (German Clinical Trials Register, DRKS00003880).
    • 11 Apr 2011 Results published in the Journal of Clinical Oncology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top